Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Arysta Lifescience North America LLC holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This action is assigned to 1 distinct examiner and 1 distinct art unit. This configuration suggests that the company's current patent prosecution is focused within the identified technical and administrative designations.
SCHLIENTZ, NATHAN W is the busiest examiner for the portfolio, with 1 pending office action. For the practitioner, this means that the 1 pending office action is subject to the specific examination style and history of SCHLIENTZ, NATHAN W. Because the portfolio involves 1 distinct examiner, the company can focus its resources on the preferences of this individual rather than managing diverse perspectives.
The involvement of 1 distinct art unit suggests that the subject matter of the pending office action is confined to a specific technical niche within the Biotechnology & Pharmaceuticals technology area. This concentration simplifies the management of the portfolio, as the prosecution is not divided across art units. The current data reflects a targeted approach to patent acquisition, with all active prosecution consolidated under these specific designations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.8% |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 15579362 | Surfactant-Stabilized Cyclohexanedioxide Oxime Formulations | SCHLIENTZ, NATHAN W | 1616 | §103 | Final Rejection | — | Pending | Dec 04, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArysta Lifescience North America LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nathan W Schlientz has the most, with 1 of Arysta Lifescience North America LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.